Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flavivirus vaccines.

J R Stephenson1

  • 1Division of Biologics, Centre for Applied Microbiology and Research, Porton Down, Salisbury, UK.

Vaccine
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Flavivirus vaccines show promise, with successful yellow fever and tick-borne encephalitis vaccines. However, challenges remain for diseases like dengue fever, necessitating further research into improved vaccine development strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of recombinant antigens as diagnostic reagents in enzyme-linked immunosorbent assays.

Methods in molecular medicine·2011
Same author

Tick-borne encephalitis virus - a review of an emerging zoonosis.

The Journal of general virology·2009
Same author

Serum levels of interleukin 6 in recently hospitalized tick-borne encephalitis patients correlate with age, but not with disease outcome.

Clinical and experimental immunology·2008
Same author

Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non-structural NS1 protein.

BMC microbiology·2005
Same author

A synthetic peptide based on the NS1 non-structural protein of tick-borne encephalitis virus induces a protective immune response against fatal encephalitis in an experimental animal model.

Virus research·2005
Same author

Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Virus genes·2004
Same journal

Immunogenicity and safety of a SARS-CoV-2 recombinant vaccine S-268024 booster vaccination versus NVX-CoV2373: Interim results from a phase 3, multicenter, randomized, observer-blind, active-controlled study.

Vaccine·2026
Same journal

Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.

Vaccine·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
See all related articles

Area of Science:

  • Virology
  • Vaccinology
  • Epidemiology

Background:

  • Flavivirus infections, including yellow fever, dengue fever, and Russian spring-summer encephalitis, have caused significant global mortality for centuries.
  • Live-attenuated vaccines have controlled yellow fever, and inactivated vaccines have reduced tick-borne encephalitis incidence in endemic areas.
  • Despite these successes, developing effective vaccines against other pathogenic flaviviruses like dengue fever remains a significant challenge.

Purpose of the Study:

  • To review the current status of flavivirus vaccine development.
  • To identify challenges and limitations in designing effective flavivirus vaccines.
  • To explore and discuss future strategies for improving flavivirus vaccine development.

Main Methods:

  • Literature review of flavivirus vaccine development.

Related Experiment Videos

  • Analysis of successes and failures in vaccine design.
  • Discussion of current and future vaccine development strategies.

    • Main Results:

    • Vaccines for yellow fever and central-European tick-borne encephalitis demonstrate successful disease control.
    • Significant hurdles persist in developing vaccines for other critical flaviviruses, such as dengue fever.
    • Various strategies for future flavivirus vaccine development are under consideration.

    Conclusions:

    • While progress has been made, particularly with yellow fever and tick-borne encephalitis vaccines, substantial challenges impede the development of broadly effective flavivirus vaccines.
    • Further research is crucial to overcome existing obstacles and explore novel approaches for flavivirus vaccine design.
    • Identifying and addressing the limitations of current strategies will be key to advancing flavivirus vaccine development for diseases like dengue fever and Russian spring-summer encephalitis.